FDA green-lights Asklepion's Cholbam; Pfizer's Australian court fight over Lipitor discounting isn't over yet;

@FiercePharma: Sinovac close to China marketing approval for hand, foot and mouth vaccine. More from FiercePharmaAsia | Follow @FiercePharma

@EricPFierce: Malaysia's CCM Duopharma Biotech ready to compete with the big boys, buying 6 plants from parent. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Imbruvica cocktail stalls CLL in new trial, raising hopes for bigger market. Article | Follow @CarlyHFierce

> The FDA approved Cholbam, a new drug from Baltimore-based Asklepion Pharmaceuticals, to treat bile acid and peroxisomal disorders in kids and adults. Release

> Australia's expert body that recommends drugs for subsidy has hit back at a pharmaceutical industry push to fast-track listings for new cancer medicines. Report

> Illinois drugmaker Akorn ($AKRX) has asked Alabama officials to return any Akorn-made drugs the state may be planning to use in executions by lethal injection. Report

> Pfizer's ($PFE) court fight over Lipitor discounting in Australia isn't over yet; the country's consumer watchdog says it will appeal a federal judge's decision that the company hadn't engaged in anticompetitive conduct. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Mayo Clinic finds a common MRI contrast agent is deposited in the brain. Report | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Tablets, apps being deployed to improve customer service in the ICU. Article | Follow @VarunSaxena2

@EmilyWFierce: $MDT and the University of Minnesota are studying hibernating bears to gain insight into treating heart disease. More | Follow @EmilyWFierce

> Olympus faces more legal pushback over endoscopes linked to UCLA superbug outbreak. Article

> Vivo Capital doubles down to close $750M U.S.-China healthcare fund. Story

> Boston Scientific implantable defibrillator gets FDA green light. Report

Biotech News

@FierceBiotech: ICYMI yesterday: Struggling GlaxoSmithKline warns of 150 R&D job cuts in Philadelphia. News | Follow @FierceBiotech

@JohnCFierce: Pfizer joins a powerhouse syndicate backing $43M round for Nimbus. News | Follow @JohnCFierce

@DamianFierce: Dear Twitter, it is my great honor to introduce FierceMadness, the 2015 Drug Name Tournament. Check it out | Follow @DamianFierce

> Retrophin bags rare disease approval, FDA voucher in $75M deal. News

> Nordic Nanovector upscales IPO as demand tops expectations. More

> Deep dive into Actelion's Uptravi data calms investors as FDA decision date nears. Story

> Nektar looks for the positive in a failed PhIII breast cancer study. Report

Biotech Research News

> Research group uses nanoparticles to deliver antibiotic. Item

> Fast-spreading CRISPR tech inspires new preclinical work on blood cancers. More

> Academic team assembles a 'homegrown' immunotoxin for blood cancers. Story

> Blood pressure drug looks promising in preventing myelin loss in MS. Article

> Rockefeller U team touts a potential psoriasis 'cure' from Boehringer. Report

Diagnostics News

> Metabolon rides on last year's success with $5M in extended financing. Story

> Illumina hits U.K. company with prenatal test patent suit. Article

> Myriad extends collaboration with BioMarin for cancer companion Dx. Item

> Invitae to focus on adding genetic tests, securing reimbursement in 2015. Report

> 23andMe launches new therapeutics group with biotech vet taking the reins. More

Pharma Marketing News

> Worried about quality at home, Chinese consumers stock up on 'Made in Japan' drugs. Item

> Judge tosses Xolair kickback suit against Novartis, Genentech. Report

> Pernix looks for a sales trifecta from 100 new Zohydro reps. Story

> Mayo docs join the revolt against rising cancer drug prices. News

> It had to happen: Apple Watch gets a drug-adherence app. More

And Finally... Aspirin may increase the risk of colorectal cancer in people with certain genetic variants, new research shows. Report

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.